Mirum’s Oral Drug Becomes First U.S. Approved Alagille Syndrome Therapy

Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Md., on Aug. 29, 2020. Andrew Kelly/Reuters

Mirum Pharmaceuticals Inc said its drug became the first U.S.-approved therapy for treating itching in patients with rare liver disorder Alagille syndrome (ALGS), and would be available for distribution immediately.

Shares of the company were briefly halted before the approval and rose as much as 8.8% to $20.40 after resumption on Wednesday.